Logo

Chiron to Use Serenex s Proteomics Technology

Sep 24, 2002

NEW YORK, Sept. 24 - Serenex today said that Chiron will use its protein-mining technology to help it uncover new drug targets.

 

Chiron will use Serenex's "functional proteome fractionation" technology and its Protein Mining tool to screen potential protein targets.

 

Serenex, which pocketed $15 million in a round of private-equity financing in mid-August, said it will hire 30 more scientists within a year to kick off a program to automate its proteomics platform. The company has also signed early-stage partnerships with Pharmacia and Pfizer and is in negotiations with two "recently-merged" companies, according to CEO Robert Dishman.

Breaking News
The Scan

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.

Seagull Microbiome Altered by Microplastic Exposure

The overall diversity and the composition at gut microbiome sites appear to coincide with microplastic exposure and ingestion in two wild bird species, according to a new Nature Ecology and Evolution study.

Study Traces Bladder Cancer Risk Contributors in Organ Transplant Recipients

In eLife, genome and transcriptome sequencing reveal mutation signatures, recurrent somatic mutations, and risky virus sequences in bladder cancers occurring in transplant recipients.

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.